Erin Watson, MD
Pain Medicine · Conway, SCNPI 1114139854
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,854 of the $9,110 with a category attached, or 75.2%. 38 manufacturers reported payments, led by Nevro Corp. at 26.8% of the total. Reporting peaked in 2019 at $3,311 and has fallen 59.1% since, to $1,355 in 2025.
Across 296 payments — averaging $30.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$2K
- Boston Scientific$2K
- Medtronic$2K
- Collegium Pharmaceutical, Inc.$545
- Radius Health, Inc.$404
- Nalu Medical, Inc.$269
- plus $2K from 32 others
What the payments were for
- Travel & lodging$2,25625%
- Food & beverage$6,85475%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPECTRA WAVEWRITER$1,209
- Senza Spinal Cord Stimulation System$993
- INTELLIS ADAPTIVESTIM$462
- Omnia$425
- INCEPTIV$140
- Senza$132
- Qutenza$127
- Nalu Neurostimulation System$121
- Monarch Platform$118
- INFINION$102
How this compares
$9,110 in reported general payments places this provider in the 75th percentile of 92 pain medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 172 | $117,708 |
| ProliaDenosumab | 41 | $70,876 |
| ForteoTeriparatide | 17 | $67,494 |
| Nucynta ErTapentadol Hcl | 31 | $45,455 |
| RelistorMethylnaltrexone Bromide | 19 | $45,344 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,513 | $38,015 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,175 | $34,780 |
| TymlosAbaloparatide | 13 | $32,848 |
| BelbucaBuprenorphine Hcl | 27 | $21,431 |
| MovantikNaloxegol Oxalate | 35 | $16,503 |
| Fentanyl | 141 | $14,394 |
| Oxycodone Hcl | 833 | $13,667 |
| OxycontinOxycodone Hcl | 26 | $11,714 |
| LinzessLinaclotide | 16 | $9,872 |
| Gabapentin | 686 | $9,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Belbuca | $545 | $184,594230 claims |
| AmgenProlia | $265 | $70,87641 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $38 | $45,34419 claims |
| Radius Health, Inc.Tymlos | $404 | $32,84813 claims |
| AbbVieLinzess, Savella | $169 | $16,93429 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $79 | $6,52119 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $18 | $5,72012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 pain medicine providers in South Carolina.
Other pain medicine in Conway
- Richard KlineConway$104K
- Phillip SmithGreenville$303K
- Channing WilloughbyMurrells Inlet$82K
- Michael WarrickSumter$50K
- Daniel AtkinsonGreenville$36K
- Michael WardenFlorence$20K
- Andrew MendelsonCharleston$19K
- Sankeerth ChallagundlaColumbia$15K
- Kevin WalkerGreenville$14K
- Matthew DaviesMurrells Inlet$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.